Hamlet Pharma has participated in a number of recent events, presenting highligts from the promising clinical studies and our future strategy. With this newsletter, we…
Read More
Hamlet Pharma enters a new business development phase involving multiple cancer indications and markets. Based on the successful outcomes of our clinical trial program, we…
Hamlet Pharma has recently delivered its 18-month report to the Euro- pean Union’s Horizon 2020 program. In their response, the EU states that the project…
Pressmeddelande Hamlet Pharma deltar på Stockholm Corporate Finance 14e Life Science Kapitalmarknadsdagar den 8 – 9 mars 2022. Catharina och Mats presenterar den 8 mars…
Hamlet-Pharma-Newsletter-Dose-escalationDownload
Read More
MON, JAN 17, 2022 12:15 CET Hamlet Pharma has previously reported the successful completion of a Phase I/II study using a 1.7 mM dose of…
FRI, JAN 14, 2022 14:59 CET To continue Hamlet Pharma’s drug development process towards Phase III trials and future commercialization, it is essential to expand…
Hamlet Pharma is increasing its focus on the company’s digital channels, to provide easier access for shareholders and the public. So far, this effort includes…
Lund October 29, 2021 It is a great pleasure to announce that Hamlet Pharma has secured theproduction of larger quantities of Alpha1H, using a stable,…
We are proud to share the positive comments from the EIC Accelerator Horizon 2020 fund. The experienced EU evaluators state that: “All required milestones and…